You are not logged in (login)

Research Center

JOBS

Infirmière de recherche

Louis Lacombe

List >

PHONEBOOK

Michel G. Bergeron

Formation
M.D.

FRCPC

No active offer

All active job offers
Principal area
Infectious and immune diseases
Address
Centre Hospitalier de l'Université Laval (CHUL)
2705, boulevard Laurier, RC-709
Québec (Québec)
CANADA G1V 4G2

Phone
+1 418-525-4444, poste 48753
Fax
+1 418-654-2715
Email
Michel.G.Bergeron@crchudequebec.ulaval.ca

 Dr. Michel G. Bergeron is a full Professor and director of the Infectious Diseases Research Centre of Laval University in Québec city, which he founded in 1974. He completed a postdoctoral fellow in microbiology and infectious diseases at Tufts University and at the Massachusetts Institute of Technology, in Boston. Dr. Bergeron is the author or co-author of 407 scientific articles, 45 book chapters, 1 100 communications in congresses and invited speaker at international symposiums, and he acted as chairman in 81 symposiums.  Dr Bergeron holds 25 patents and is the recipient of more than 19 million $ grants as principal investigator or co-investigator. His main research projects consist in the development of DNA-based diagnostic tests for the detection of microbes and their associated antibiotic resistance genes in less than one hour compared to the >48 hours still requested in conventional microbiology laboratories today. To perform this, Dr Bergeron created Infectio Diagnostic, which merged with B-D Diagnostic-GeneOhm. Five of the tests he has developed are already on the market, for the detection of streptococci, staphylococci, enterococci and C. difficile. By combining genomics, DNA microarrays, microfluidic networks, and nanotechnology, Dr Bergeron is developing a ‘compact disk’ that will allow simultaneous detection of various microbes within 15 minutes at the point-of-care, based on their DNA fingerprints. To achieve this goal, Dr Bergeron has created GenePOC, a company dedicated to the development of new diagnostic tools. Dr Bergeron has also developed a microbicidal gel, the Invisible Condom®, to prevent women from contracting HIV/AIDS and other sexually transmitted diseases. Dr Bergeron has also been working on several topics including the pathogenesis of pneumonia. In recognition of his outstanding scientific career and for life-time achievements, Dr Bergeron was recently nominated Recipient of the Frost & Sullivan 2013 North American Entrepreneurial Company of the Year Award in the Molecular Diagnostics Market to GenePOC Inc, Recipient of the Queen Elizabeth II Diamond Jubilee Medal, Appointed member of the Order of Canada (C.M.), Officer of the ‘Ordre du Québec’ received by the premier of the Province of Québec; he was the Laureate of the ‘Transfer Award’ at the 11th edition of the Innovation-Research Contest 2008 of the Association of Health Technologies Industry; Laureate of the 2007 Genome Quebec’s ‘Biotechnology Award of Tomorrow’ at Genesis Awards Gala; Laureate of the ‘Wilder-Penfield prize’ (Prix du Québec), the highest distinction of the Government of the Province of Québec for outstanding achievements in biomedical research; Laureate of the ‘Prix de l'œuvre scientifique’ by the Association des Médecins de langue française du Canada; Recipient of the ‘Prix Louis Pasteur’ and of the ‘Médecin de mérite’ award.

Research team

PROFESSOR :

BERGERON, Michel G.

PROJECT LEADERS :

BISSONNETTE, Luc

BOISSINOT, Maurice

HULETSKY, Ann

OMAR, Rabeea F.

STEWART, Gale

Ph.D. STUDENTS :

BOISSINOT, Karel

Daher, Rana

M.Sc. STUDENTS :

Girard, Laurie

 

 

RESEARCH PROFESSIONNALS :

BASTIEN, Martine

BERNIER, Marthe

BÉRUBÉ, Ève

BOUDREAU, Dominique

BRESSON, Eva

FRENETTE, Johanne

GAGNON, Martin

HÉLIE, Marie-Claude 

SIMARD, Jean-Luc

Vallée, Marilyse

 
POSTDOCT TRAINEE :
 
AHMED OUAMEUR, Amin
 
 :PERSONNEL ADMINISTRATIF

 MERCIER, Guylaine

Recent publications (see all publication from this researcher)

Huletsky A, Bergeron MG. Bacterial genotypic drug resistance assays (Chapter 85)  In: Mayers DL, Sobel JD, Ouellette M, Kaye KS, Marchaim D, eds.  Antimicrobial Drug Resistance. Mechanisms of Drug Resistance, Volume 2 : Springer International Publishing, 2017. p..
Maheux AF, Boudreau DK, Berube E, Boissinot M, Raymond F, Brodeur S, Corbeil J, Brightwell G, Broda D, Omar RF, Bergeron MG. Draft Genome Sequence of Romboutsia maritimum sp. nov. Strain CCRI-22766T, Isolated from Coastal Estuarine Mud. Genome announcements,  2017. Epub
Maheux AF, Bouchard S, Berube E, Bergeron MG. Comparison of MI, Chromocult(R) coliform, and Compass CC chromogenic culture-based methods to detect Escherichia coli and total coliforms in water using 16S rRNA sequencing for colony identification. Journal of water and health,  2017. 15: 353-359
Bissonnette L, Maheux AF, Bergeron MG. CRENAME, A Molecular Microbiology Method Enabling Multiparametric Assessment of Potable/Drinking Water. Methods in molecular biology (Clifton, N.J.) ,  2017. 1620: 141-151
Hanchi H, Hammami R, Gingras H, Kourda R, Bergeron MG, Ben Hamida J, Ouellette M, Fliss I. Inhibition of MRSA and of Clostridium difficile by durancin 61A: synergy with bacteriocins and antibiotics. Future microbiology,  2017. 12: 205-212
Maheux AF, Boudreau DK, Berube E, Boissinot M, Cantin P, Raymond F, Corbeil J, Omar RF, Bergeron MG. Draft Genome Sequence of Romboutsia weinsteinii sp. nov. Strain CCRI-19649T Isolated from Surface Water. Genome announcements,  2017. Epub
Maheux AF, Bouchard S, Berube E, Bergeron MG. Rapid molecular identification of fecal origin-colonies growing on Enterococcus spp.-specific culture methods. Journal of water and health,  2017. 15: 239-250
Bissonnette L, Bergeron MG. Portable devices and mobile instruments for infectious diseases point-of-care testing. Expert review of molecular diagnostics,  2017. 17: 471-494
Maheux AF, Sellam A, Piche Y, Boissinot M, Pelletier R, Boudreau DK, Picard FJ, Trepanier H, Boily MJ, Ouellette M, Roy PH, Bergeron MG. Use of phylogenetical analysis to predict susceptibility of pathogenic Candida spp. to antifungal drugs. Journal of microbiological methods,  2016. 131: 51-60
Raymond F, Ouameur AA, Deraspe M, Iqbal N, Gingras H, Dridi B, Leprohon P, Plante PL, Giroux R, Berube E, Frenette J, Boudreau DK, Simard JL, Chabot I, Domingo MC, Trottier S, Boissinot M, Huletsky A, Roy PH, Ouellette M, Bergeron MG, Corbeil J. The initial state of the human gut microbiome determines its reshaping by antibiotics. The ISME journal,  2016. 10: 707-20
© 2017 All rights reserved CRCHU de Québec